By Fineline Cube 
Shanghai OPM Biosciences Co., Ltd (SHA: 688293), a China-based cell culture-focused Contract Development and Manufacturing Organization (CDMO), announced plans to acquire 100% stake in PharmaLegacy Laboratories, a pre-clinical biologics Contract Research Organization (CRO), for a consideration of RMB 1.45 billion (USD 202 million).
Transaction Benefits
Upon completion of the transaction, OPM Bio will gain access to PharmaLegacy’s preclinical research client resources. This will enable early-stage promotion of PharmaLegacy’s cell culture media products and biologics CDMO services during drug development. The acquisition is expected to expand OPM’s potential client base, increase early-stage R&D pipeline opportunities, and secure innovative drug candidates with strong commercialization potential. It will also create synergies between upstream and downstream business segments.
Collaborative Advantages
Concurrently, PharmaLegacy can refer its cell culture media and CDMO partners to utilize OPM Bio’s preclinical pharmacodynamic research services, establishing complementary business advantages.
Global Expansion Strategy
For global expansion, PharmaLegacy will leverage its established overseas sales network and team to accelerate international market penetration for cell culture products and biologics CDMO services.-Fineline Info & Tech